Pharmacokinetics and pharmacodynamics in the development of antifungal compounds

Current Opinion in Investigational Drugs

Volumn 4, Issue 8, 2003, Pages 991-998

  Andes, David ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antifungal; Drug binding; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GATIFLOXACIN; GEMIFLOXACIN; POLYENE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAVUCONAZOLE; SITAFLOXACIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG PENETRATION; DRUG URINE LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; OUTCOMES RESEARCH; PHARMACODYNAMICS; PREDICTION; REVIEW; STREPTOCOCCUS INFECTION;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TRIAZOLES;

EID: 0141719603     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 26(1):1-12. Excellent review of pharmacokinetics and pharmacodynamics.
2. Andes D, Craig WA: In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations. Antimicrob Agents Chemother (1998) 42(9):2375-2379.
3. Craig WA, Andes D: Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J (1996) 15(3):255-259.
4. Dudley MN, Ambrose PG: Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: Ready for prime time. Curr Opin Microbiol (2000) 3(5):515-521. Excellent review of the clinicla use of population pharmacokinetics and stochastic modeling.
5. Development of in Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guidelines, 2nd Edition. National Committee for Clinical Laboratory Standards, Wayne, PA, USA (2000): Document M23-A2.
6. Andes D, Van Ogtrop M: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother (1999) 43(9):2116-2120.
7. Andes D, Stamsted T, Conklin R: Pharmacodynamics of amphotericin B in a neutropenic murine disseminated-candidiasis model. Antimicrob Agents Chemother (2001) 45(3):922-926.
8. Andes D, Van Ogtrop M: In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother (2000) 44(4):938-942.
9. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeast; Approved Standard. National Committee for Clinical Laboratory Standards, Wayne, PA, USA (1997): Document M27-A.
10. Ernst EJ, Klepser ME, Pfaller MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 44(4):1108-1111.
11. Klepser MW, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA: Antifungal pharmacodynamic characterization of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 41(6):1392-1395.
12. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2002) 46(6):1857-1869.
13. Walsh TJ, Lee JW, Roilides E, Francis P, Bacher J, Lyman CA, Pizzo PA: Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: Approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis (1992) 14(Suppl. 1):139-147. Review of animal models used in antifungal drug development.
14. Andes DR, Craig WA: Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am (1999) 13(3):595-618.
15. Perfect JR: Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. Rev Infect Dis (1990) 12(Supp 3):299-302.
16. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis (2000) 182(1):274-282.
17. Frimodt-Moller N: Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents (2002) 19(6):546-553.
18. Beauchamp D, Bergeron MG: Pharmacologic basis for the treatment of pyelonephritis. Curr Infect Dis Rep (1999) 1(4):371-378.
19. Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents (2002) 19(4):261-268. Review of animal model pharmacodynamics.
20. Kunin CM, Craig WA, Kornguth M, Monson R: Influence of binding on the pharmacological activity of antibiotics. Ann NY Acad Sci (1973) 226:214-224.
21. Craig WA, Suh B: Protein binding and the antimicrobial effects: Methods for the determination of protein binding. In: Antibiotics in Laboratory Medicine, 4th Edition. Lorian V (Ed), Williams and Wilkins, Baltimore, MD, USA (1996):296-329.
22. Andes D: In vivo pharmacodynamics of antifungal drugs in the treatment of candidiasis. Antimicrob Agents Chemother (2003) 47(4):1179-1186. Review of antifungal pharmacodynamics.
23. Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R: In vivo pharmacodynamics of HMR 3270, a glucan-synthase inhibitor in a murine candidiasis model. Antimicrob Agents Chemother (2003) 47(4):1187-1192.
24. Andes D, Marchillo K, Stamstad T, Conklin R: In vivo characterization of the pharmacodynamics of a new triazole, ravuconazole in a murine candidiasis model. Antimicrob Agents Chemother (2003) 47(4):1193-1199.
25. Craig WA, Gudmundsson S: Postantibiotic effect. In: Antibiotics in Laboratory Medicine, 4th Edition. Lorian V (Ed), Williams and Wilkins, Baltimore, MD, USA (1996):296-329.
26. Turnidge JD, Gudmundsson S, Vogelman B, Craig WA: The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother (1994) 34(1):83-92.
27. Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, Kaw P, Shayegani M, Taber H, Miller MH: Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother (1998) 42(4):1105-1109. Study demonstrating the importance of the AUC/MC parameter for triazoles.
28. Andes DR, Van Ogtrop ML, Craig WA: Impact of neutrophils on the in vivo activity of fluoroquinolones. Abstracts of the Infectious Diseases Society of America (1999) 37:Abs 73.
29. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M: Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. J Am Med Assoc (1988) 279(2):125-129.
30. Ambrose PG, Grasela DM: The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis (2000) 38(3):151-157.
31. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother (2001) 45(1):13-22.
32. US Food and Drug Administration, Rockville, MD, USA (2003). www.FDA.gov
33. Dodds ES, Drew RH, Perfect JR: Antifungal pharmacodynamics: Review of the literature and clinical applications. Pharmacotherapy (2000) 20(11):1335-1355.
34. Groll AH, Piscitelli SC, Walsh TJ: Antifungal pharmacodynamics: Concentration-effect relationships in vitro and in vivo. Pharmacotherapy (2001) 21(8 Pt 2):S133-S148. Review of in vitro and in vivo antifungal pharmacodynamics.
35. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW: Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev (2001) 14(4):643-658. Review of the state of in vitro susceptibility testing with antifungals.
36. Rogers TE, Galgiani JN: Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 30(3):418-422.
37. Sorensen K, Corcoran F, Chen S, Clark D, Tembe V, Lomovskaya O, Dudley M: Pharmacodynamic assessment of efflux- and target-based resistance to fluconazole on efficacy against C albicans in a mouse kidney infection model. ICAAC (1999) 39:Abs 1271.
38. Van't Wout J, Mattie H, Van Furth R: Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother (1989) 33(2):147-151.
39. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL: Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro and in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis (1997) 24(2):235-247. Excellent review of clinical data available for the development of susceptibility breakpoints for antifungals.
40. Lee SC, Fung CP, Huang JS, Tsai CJ, Chen KS, Chen HY, Lee N, See LC, Shieh WB: Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother (2000) 44(10):2715-2718.
41. Clancy CJ, Kauffman CA, Morris A, Nguyen ML, Tanner DC, Snydman DR, Yu VL, Nguyen MH: Correlation of fluconazole MIC and response to therapy for patients with candidemia due to C albicans and non-C albicans spp: Results of a multicenter prospective study of candidemia. Abstracts of the Infectious Diseases Society of America (1998) 36:Abs 98.